Implementation of DVT

Similar documents
Trust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Traditional anticoagulants

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

DVT/PE Management with Rivaroxaban (Xarelto)

East Kent Prescribing Group

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Venous and Lymphatic Disorders

Overview of the TJC/CMS VTE Core Measures

PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser

Venous thromboembolism: reducing the risk. Quick reference guide. Issue date: January 2010

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

La Profilassi del Tromboembolismo Venoso in Medicina

NIMC VTE Prophylaxis Section Audit and Reporting Tool User Guide

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

3/3/2015. Patrick Cobb, MD, FACP March 2015

.php?t=943 for scoring (divided evidence- and Low, Mod, High- risk) consensus-based)

Dabigatran (Pradaxa) Guidelines

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults

Confirmed Deep Vein Thrombosis (DVT)

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Recommendations: Other Supportive Therapy of Severe Sepsis*

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013

NHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL AAOS Clinical Practice Guidelines Unit

ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE

Guideline for managing patients on Dabigatran (Pradaxa ) Statewide

Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Introduction. Background to this event. Raising awareness 09/11/2015

How To Manage An Anticoagulant

Prevention of Venous Thromboembolism

Bridging anticoagulation: the peri-procedural management of patients on oral anticoagulants (excluding neurosurgery)

0.9% Sodium Chloride injection may be used in most cases.

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Prostate Assessment Pathway Prostate Biopsy Alerts

*** Drug Safety Alert ***

Preventing Blood Clots in Adult Patients. Information For Patients

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010

Pathway for the management of DVT in primary Care

Bios 6648: Design & conduct of clinical research

Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )

Chronic Obstructive Pulmonary Disease (COPD) Admission Order Set

Experience matters: Practical management in your hospital

CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10

TSOAC Initiation Checklist

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Complication Prevention

Updates to the Alberta Human Services Drug Benefit Supplement

How To Take Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

New Oral Anticoagulants. How safe are they outside the trials?

Anticoagulant therapy

Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to

Safe Management of Anticoagulants in WA hospitals

DEEP VENOUS THROMBOSIS PROPHYLAXIS IN SURGICAL PATIENTS

PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

The Role of the Newer Anticoagulants

9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

National Patient Safety Goals Effective January 1, 2015

New Oral Anticoagulants

University of Illinois at Chicago College of Pharmacy. Hospital Compliance with Proposed JCAHO Performance Measures for VTE

A Prospective, Controlled Trial of a Pharmacy-Driven Alert System to Increase. Thromboprophylaxis Rates in Medical Inpatients

VTE Virtual Learning Series #1: Preventing VTE: Evidence and Execution

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

(a) New Oral Anticoagulants & (b) Neuropathic Pain

Building a Safe Anticoagulation Program By knowing that Safety is not about numbers, Safety is about an attitude..

XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

National Patient Safety Goals Effective January 1, 2015

Thromboprophylaxis Guidelines for Adult Patients in:

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS

Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients

Heparin Induced Thrombocytopenia

Dabigatran & Rivaroxaban Rat Poison in Better Packaging?

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Joseph A. Caprini, MD, MS, FACS, RVT

T.E.D. Anti-Embolism Stockings Nursing Procedure Guide. Sizing and application for optimal benefit

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

NWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.

Sign up to receive ATOTW weekly - worldanaesthesia@mac.com

Cardiac Diseases and Therapies ATRIAL FIBRILLATION DABIGATRAN CLINICIAN SUMMARY

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE

Thrombosis and Hemostasis

Transcription:

Implementation of DVT Prophylaxis

On admission to ICU All patients should be assessed for their risk of venous thromboembolism (VTE) Start them on either mechanical prophylaxis or pharmacological prophylaxis or a combination if not contraindicated

ABSOLUTE RISK FOR VTE Patient category Low risk eg. medical patients, immobilization, use of pharmacologic paralysis or sedation, heart failure Moderate risk eg. general surgery, major gynecologic surgery, major urologic surgery, sepsis, vasopressor use, active medical condition High risk eg. stroke, neurosurgery, previous VTE Highest risk eg. spinal cord injury, major trauma hip/knee arthroplasty, hip fracture surgery Recommendation Mechanical prophylaxis LMWH or LDUH S/C Heparin 5,000 units 12 hourly in combination with mechanical prophylaxis LMWH or LDUH S/C Heparin 5,000 units 8 hourly in combination with mechanical prophylaxis LMWH in combination with mechanical prophylaxis

Mechanical prophylaxis methods graded compression elastic stockings thigh-length antiembolism stockings intermittent pneumatic compression

Pharmacological modalities 1. Low dose unfractionated heparin (LDUH) S/C heparin 5,000 units 8 hourly (high risk) or 12 hourly (moderate risk) 2. Low molecular weight heparin (LMWH) 2. Low molecular weight heparin (LMWH) e.g. S/C enoxaparin 40mg daily when creatinine clearance > 30ml/min or 30mg daily when creatinine clearance < 30ml/min

Withhold heparin when.. platelet count decreases 30 to 50% of initial count platelet count is less than 100,000 /ml of blood The platelet count has to be done daily

Withhold heparin when.. INR > 1.5 aptt ratio > 1.5 Patient has clinical signs of bleeding Patient is on renal replacement therapy

Neurosurgical patients Use mechanical prophylaxis methods e.g. graded compression elastic stockings, thigh-length antiembolism stockings or intermittent pneumatic compression Start LMWH or s/c heparin after 72 hours of hospital admission or craniotomy

Points to note Do not stop heparin if patients are scheduled for procedures or surgery unless there is a particularly high bleeding risk The insertion and removal of epidural catheters The insertion and removal of epidural catheters should coincide with the nadir of the anticoagulant effect. The last dose of LMWH should be 12 hours prior to removal of catheter and can be restarted 2 hours later

ALGORITHM FOR VTE PROPHYLAXIS IN ICU

ICU ADMISSION BLEEDING RISK HIGH Mechanical prophylaxis (Graduated compression stocking or Intermittent Pneumatic compression) until bleeding risk resolves LOW Mechanical prophylaxis MODERATE s/c heparin 5000 U 12hourly or LMWH in combination with mechanical prophylaxis USUAL VTE RISK CATEG ORY HIGH s/c heparin 5000 U 8hourly or LMWH in combination with mechanical prophylaxis HIGHEST LMWH in combinatio n with mechanical prophylaxis

Notes Withhold heparin when platelet count decreases 30 to 50% from the initial count or when the platelet count is less than 100,000 /ml or when INR > 1.5 or when aptt ratio >1.5 or when there is clinical bleeding or when patient is on renal replacement therapy Start heparin only after 72 hours of hospital admission or craniotomy in all neurosurgical patients Continue heparin for procedures or surgery unless there is a particularly high bleeding risk Remember to time the insertion and removal of epidural catheters with the dose of heparin

Recommendations to improve compliance of DVT prophylaxis Include DVT prophylaxis as part of the ICU order on admission in the drug chart Include DVT prophylaxis as an item for discussion on daily ward rounds Empower nurses to remind doctors to prescribe DVT prophylaxis if the drug had not been prescribed Empower pharmacy to review orders for patients in the ICU to ensure that DVT prophylaxis has been prescribed and carried out by nurses Post compliance with the intervention in a prominent place in your ICU to encourage change and motivate staff.